A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy

Autor: Mj, Clemons, Marshall E, Dürig J, Watanabe K, Howell A, Miles D, Helena Earl, Kiernan J, Griffiths A, Towlson K, DeTakats P, Ng, Testa, Dougal M, Mg, Hunter, Lm, Wood, Lg, Czaplewski, Millar A, Tm, Dexter, Bi, Lord

Publikováno v: Europe PubMed Central

BB-10010 is a variant of the human form of macrophage inflammatory protein-1alpha (MIP-1alpha), which has been shown in mice to block the entry of hematopoietic stem cells into S-phase and to increase their self-renewal capacity during recovery from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c0b0ab357fac69d420433720339b5863
https://pubmed.ncbi.nlm.nih.gov/9716580

Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.

Autor: Beltran-Bless AA; Division of Medical Oncology, The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada., Clemons MJ; Division of Medical Oncology, The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Fesl C; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria., Greil R; Salzburg Cancer Research Institute; 3d Medical Department, Paracelsus Medical University Salzburg; Cancer Cluster Salzburg, Austria., Pond GR; Ontario Clinical Oncology Group, Department of Oncology, McMaster University, Hamilton, Ontario, Canada., Balic M; Division of Oncology, Department of Internal Medicine and Comprehensive Cancer Center, Medical University of Graz, Graz, Austria., Vandermeer L; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Bjelic-Radisic V; Breast Unit, Helios University Hospital Wuppertal, Wuppertal Germany, University Witten/Herdecke, Germany; And Department of Gynecology and Obstetrics, Medical University of Graz, Graz, Austria., Singer CF; Department of Gynecology and Gynecological Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Steger GG; Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria., Helfgott R; Department of Surgery and Breast Health Center, Ordensklinikum Linz, Linz, Austria., Egle D; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria., Sölkner L; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria., Gampenrieder SP; Salzburg Cancer Research Institute; 3d Medical Department, Paracelsus Medical University Salzburg; Cancer Cluster Salzburg, Austria., Kacerovsky-Strobl S; Breast Health Center, St. Francis Hospital Vienna, Vienna, Austria., Suppan C; Division of Oncology, Department of Internal Medicine and Comprehensive Cancer Center, Medical University of Graz, Graz, Austria., Ritter M; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria., Rinnerthaler G; Ontario Clinical Oncology Group, Department of Oncology, McMaster University, Hamilton, Ontario, Canada., Pfeiler G; Department of Gynecology and Gynecological Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Fohler H; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria., Hlauschek D; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria., Hilton J; Division of Medical Oncology, The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Gnant M; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: michael.gnant@meduniwien.ac.at.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Feb; Vol. 180, pp. 108-116. Date of Electronic Publication: 2022 Dec 10.

Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review.

Autor: Ng TL; Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, K1H 8L6, Canada. teng@toh.ca.; Ottawa Hospital Research Institute, Ottawa, ON, Canada. teng@toh.ca.; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. teng@toh.ca., Tu MM; Ottawa Hospital Research Institute, Ottawa, ON, Canada., Ibrahim MFK; Division of Clinical Sciences, Medical Oncology, Northern Ontario School of Medicine, Thunder Bay, ON, P7B 5E1, Canada., Basulaiman B; Comprehensive Cancer Center -Medical Oncology, King Fahad Medical City, Riyadh, Saudi Arabia., McGee SF; Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, K1H 8L6, Canada.; Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada., Srikanthan A; Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, K1H 8L6, Canada.; Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada., Fernandes R; Division of Medical Oncology, London Regional Cancer Program, London Health Sciences Centre, University of Western Ontario, London, ON, Canada., Vandermeer L; Ottawa Hospital Research Institute, Ottawa, ON, Canada., Stober C; Ottawa Hospital Research Institute, Ottawa, ON, Canada., Sienkiewicz M; Ottawa Hospital Research Institute, Ottawa, ON, Canada., Jeong A; Ottawa Hospital Research Institute, Ottawa, ON, Canada., Saunders D; Ottawa Hospital Research Institute, Ottawa, ON, Canada., Awan AA; Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, K1H 8L6, Canada.; Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada., Hutton B; Ottawa Hospital Research Institute, Ottawa, ON, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada., Clemons MJ; Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, K1H 8L6, Canada.; Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2021 Feb; Vol. 29 (2), pp. 925-943. Date of Electronic Publication: 2020 Jun 13.

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.

Autor: Van Poznak C; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Somerfield MR; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Barlow WE; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Biermann JS; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Bosserman LD; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Clemons MJ; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Dhesy-Thind SK; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Dillmon MS; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Eisen A; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Frank ES; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Jagsi R; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Jimenez R; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Theriault RL; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Vandenberg TA; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Yee GC; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE., Moy B; Catherine Van Poznak, J. Sybil Biermann, and Reshma Jagsi, University of Michigan, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Linda D. Bosserman, City of Hope, Duarte, CA; Mark J. Clemons, The Ottawa Hospital Cancer Centre, Ottawa; Sukhbinder K. Dhesy-Thind, Juravinski Hospital and Cancer Centre, Hamilton; Andrea Eisen, Theodore A. Vandenberg, London Regional Cancer Program, London, Ontario, Canada; Melissa S. Dillmon, Harbin Clinic, Rome, GA; Elizabeth S. Frank, Dana-Farber Cancer Institute; Rachel Jimenez, Beverly Moy, Massachusetts General Hospital, Boston, MA; Richard L. Theriault, MD Anderson Cancer Center, Houston, TX; and Gary C. Yee, University of Nebraska Medical Center, Omaha, NE.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Dec 10; Vol. 35 (35), pp. 3978-3986. Date of Electronic Publication: 2017 Oct 16.

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.

Autor: Trudeau ME; Sunnybrook Odette Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5 Canada., Chapman JA; NCIC Clinical Trials Group, Queen's University, 10 Stuart Street, Kingston, ON K7L 3N6 Canada., Guo B; Advanced Medical Research Institute of Canada (AMRIC), 41 Ramsey Lake Road, Sudbury, ON P3E 5J1 Canada., Clemons MJ; The Ottawa Hospital Cancer Centre, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6 Canada., Dent RA; Sunnybrook Odette Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5 Canada., Jong RA; Sunnybrook Odette Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5 Canada., Kahn HJ; Sunnybrook Odette Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5 Canada., Pritchard KI; Sunnybrook Odette Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5 Canada., Han L; NCIC Clinical Trials Group, Queen's University, 10 Stuart Street, Kingston, ON K7L 3N6 Canada., O'Brien P; NCIC Clinical Trials Group, Queen's University, 10 Stuart Street, Kingston, ON K7L 3N6 Canada., Shepherd LE; NCIC Clinical Trials Group, Queen's University, 10 Stuart Street, Kingston, ON K7L 3N6 Canada., Parissenti AM; Advanced Medical Research Institute of Canada (AMRIC), 41 Ramsey Lake Road, Sudbury, ON P3E 5J1 Canada.

Publikováno v: SpringerPlus [Springerplus] 2015 Oct 21; Vol. 4, pp. 631. Date of Electronic Publication: 2015 Oct 21 (Print Publication: 2015).